Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines
Open Access
Abstract
Efficient and targeted delivery of a DNA payload is vital for developing safe gene therapy. Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlight. Adenovirus vectors can be used in gene therapy by altering the wild-type virus and making it replication-defective; specific viral genes can be removed and replaced with a segment that holds a therapeutic gene, and this vector can be used as delivery vehicle for tissue specific gene delivery. Modified conditionally replicative–oncolytic adenoviruses target tumors exclusively and have been studied in clinical trials extensively. This comprehensive review seeks to offer a summary of adenovirus vectors, exploring their characteristics, genetic enhancements, and diverse applications in clinical and preclinical settings. A significant emphasis is placed on their crucial role in advancing cancer therapy and the latest breakthroughs in vaccine clinical trials for various diseases. Additionally, we tackle current challenges and future avenues for optimizing adenovirus vectors, promising to open new frontiers in the fields of cell and gene therapies.Keywords
Funding Information
- Powell Gene Therapy Center (U01-NS116752-01A1(MC), R01 HL139708-02 (BJB))
This publication has 209 references indexed in Scilit:
- Merck Ad5/HIV induces broad innate immune activation that predicts CD8 + T-cell responses but is attenuated by preexisting Ad5 immunityProceedings of the National Academy of Sciences, 2012
- Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine VectorThe Journal of Infectious Diseases, 2012
- Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP ComponentPLOS ONE, 2011
- A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)PLOS ONE, 2011
- Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of AdenoviridaeJournal of Virology, 2010
- The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in AdultsAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor β1-induced apoptosisVirus Research, 2009
- The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Journal of Experimental Medicine, 2008
- Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma InterferonInfection and Immunity, 2007
- Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasisVaccine, 2007